Zhang Yang, Li Yingnan, Zhou Min, Yang Lichang
Faculty of Life science and Technology, Kunming University of Science and Technology, Kunming, 650500, China.
Department of Orthopedics and Traumatology, Wuxi Second Hospital of Traditional Chinese Medicine, Wuxi, Jiangsu, 214000, China.
J Orthop Surg Res. 2025 Jul 26;20(1):710. doi: 10.1186/s13018-025-06120-4.
To explore the role and mechanism of miR-122-5p in the process of fracture healing following a Pilon fracture, as well as to further assess the clinical significance of this molecule as a potential diagnostic marker for fracture nonunion.
The expression levels of miR-122-5p were examined in patients with Pilon fracture healed and nonunion, respectively. ROC analysis was employed to evaluate the diagnostic value of miR-122-5p in identifying fracture nonunion, while logistic regression identified its risk factors. The effects of miR-122-5p on the proliferation, apoptosis, and osteogenic differentiation markers of osteoblasts were analyzed by CCK-8 assays, flow cytometry, RT-qPCR, and ALP assay kit. Additionally, DLR and RIP assays validated miR-122-5p targeting PDCD4.
Serum miR-122-5p was significantly under-expressed in patients with fracture nonunion, whereas PDCD4 exhibits a notable over-expressed. Serum miR-122-5p can predict non-union of fractures, with a sensitivity of 90.82% and a specificity of 78.33%. Low miR-122-5p expression is a potential risk factor for fracture nonunion. The overexpression of miR-122-5p enhanced the proliferation ability of osteoblasts, inhibited cell apoptosis, and upregulated the expressions of ALP, OCN, and RUNX2; knockdown of miR-122-5p elicits opposite effect. PDCD4 is a direct target of miR-122-5p. The osteoblast dysfunction induced by miR-122-5p inhibitors can be reversed by down-regulating PDCD4.
Diminished miR-122-5p emerge as a potential prognostic indicator for nonunion in Pilon fractures. miR-122-5p accelerates the healing of Pilon fractures by targeting and inhibiting PDCD4.
探讨miR-122-5p在Pilon骨折后骨折愈合过程中的作用及机制,并进一步评估该分子作为骨折不愈合潜在诊断标志物的临床意义。
分别检测Pilon骨折愈合患者和骨折不愈合患者中miR-122-5p的表达水平。采用ROC分析评估miR-122-5p在诊断骨折不愈合中的价值,同时通过逻辑回归确定其危险因素。通过CCK-8法、流式细胞术、RT-qPCR和碱性磷酸酶检测试剂盒分析miR-122-5p对成骨细胞增殖、凋亡及成骨分化标志物的影响。此外,通过双荧光素酶报告基因实验(DLR)和RNA免疫沉淀实验(RIP)验证miR-122-5p靶向程序性细胞死亡蛋白4(PDCD4)。
骨折不愈合患者血清miR-122-5p显著低表达,而PDCD4显著高表达。血清miR-122-5p可预测骨折不愈合,敏感性为90.82%,特异性为78.33%。低miR-122-5p表达是骨折不愈合的潜在危险因素。miR-122-5p过表达增强了成骨细胞的增殖能力,抑制细胞凋亡,并上调碱性磷酸酶(ALP)、骨钙素(OCN)和Runx相关转录因子2(RUNX2)的表达;敲低miR-122-5p则产生相反的效果。PDCD4是miR-122-5p的直接靶点。下调PDCD4可逆转miR-122-5p抑制剂诱导的成骨细胞功能障碍。
miR-122-5p表达降低是Pilon骨折不愈合的潜在预后指标。miR-122-5p通过靶向抑制PDCD4促进Pilon骨折愈合。